{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:29:37Z","timestamp":1761092977767,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.urolonc.2016.07.017","type":"journal-article","created":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T03:29:20Z","timestamp":1475292560000},"page":"32.e9-32.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells"],"prefix":"10.1016","volume":"35","author":[{"given":"Josef","family":"Mang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstanze","family":"Merkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Sch\u00fcler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanis","family":"Tolstov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jielin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Hohenfellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Duensing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2016.07.017_bib1","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2016.07.017_bib2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2011.117","article-title":"The changing therapeutic landscape of castration-resistant prostate cancer","volume":"8","author":"Yap","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.07.017_bib3","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2016.07.017_bib4","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2016.07.017_bib5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl J Med"},{"key":"10.1016\/j.urolonc.2016.07.017_bib6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2016.07.017_bib7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2016.07.017_bib8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2016.07.017_bib9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1586\/14737140.2015.1074042","article-title":"Should docetaxel be administered earlier in prostate cancer therapy?","volume":"15","author":"Graff","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.urolonc.2016.07.017_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2016.07.017_bib11","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1158\/0008-5472.CAN-12-0783","article-title":"Androgen receptor on the move: boarding the microtubule expressway to the nucleus","volume":"72","author":"Thadani-Mulero","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.07.017_bib12","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1158\/0008-5472.CAN-12-1857","article-title":"FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57","volume":"73","author":"Cuevas","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.07.017_bib13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0026-895X(24)23132-1","article-title":"Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines","volume":"60","author":"McDaid","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.urolonc.2016.07.017_bib14","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ijc.11413","article-title":"ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells","volume":"107","author":"Zelivianski","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2016.07.017_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2009.01.022","article-title":"Targeting the RAF-MEK-ERK pathway in cancer therapy","volume":"283","author":"Montagut","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.urolonc.2016.07.017_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/2159-8274.CD-10-0022","article-title":"Characterization of KRAS rearrangements in metastatic prostate cancer","volume":"1","author":"Wang","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2016.07.017_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","article-title":"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study","volume":"14","author":"J\u00e4nne","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2016.07.017_bib18","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","article-title":"Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer","volume":"71","author":"Darshan","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.07.017_bib19","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","article-title":"Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer","volume":"70","author":"Zhu","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.07.017_bib20","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/jnci\/92.23.1941","article-title":"Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens","volume":"92","author":"Mucci","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2016.07.017_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/tbj.12059","article-title":"Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women","volume":"19","author":"Ferguson","year":"2013","journal-title":"Breast J"},{"key":"10.1016\/j.urolonc.2016.07.017_bib22","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/bjc.2014.402","article-title":"Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role","volume":"111","author":"Warth","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2016.07.017_bib23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1078-0432.CCR-14-1358","article-title":"Novel actions of next-generation taxanes benefit advanced stages of prostate cancer","volume":"21","author":"de Leeuw","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2016.07.017_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1570-0232(02)00659-1","article-title":"Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma","volume":"783","author":"Parise","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.urolonc.2016.07.017_bib25","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1242\/jcs.022103","article-title":"Structural basis for the nuclear import of the human androgen receptor","volume":"121","author":"Cutress","year":"2008","journal-title":"J Cell Sci"},{"key":"10.1016\/j.urolonc.2016.07.017_bib26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.tranon.2015.11.004","article-title":"Prognostic significance and functional role of CEP57 in prostate cancer","volume":"8","author":"Mang","year":"2015","journal-title":"Transl Oncol"},{"key":"10.1016\/j.urolonc.2016.07.017_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2016.07.017_bib28","first-page":"1981","article-title":"Constitutive activation of the Ras\/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells","volume":"63","author":"Bakin","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.07.017_bib29","first-page":"1975","article-title":"Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4\u20132 prostate cancer cells","volume":"63","author":"Bakin","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.07.017_bib30","article-title":"MEK in cancer and cancer therapy","author":"Neuzillet","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.urolonc.2016.07.017_bib31","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1158\/1535-7163.MCT-10-1033","article-title":"Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer","volume":"10","author":"Gioeli","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2016.07.017_bib32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2016.07.017_bib33","first-page":"5548","article-title":"ERG induces taxane resistance in castration-resistant prostate cancer","volume":"5","author":"Galletti","year":"2014"},{"key":"10.1016\/j.urolonc.2016.07.017_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ccr.2012.07.016","article-title":"Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells","volume":"22","author":"Domingo-Domenech","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2016.07.017_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12964-015-0089-7","article-title":"Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells","volume":"13","author":"Selvaraj","year":"2015","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.urolonc.2016.07.017_bib36","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ctrv.2014.02.003","article-title":"Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer","volume":"40","author":"Brechbiel","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2016.07.017_bib37","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1038\/sj.onc.1203032","article-title":"Rapid signalling by androgen receptor in prostate cancer cells","volume":"18","author":"Peterziel","year":"1999","journal-title":"Oncogene"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916302034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916302034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:09:39Z","timestamp":1761041379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143916302034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1078143916302034"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.07.017","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}